# Durvalumab in Pediatric and Adolescent Patients

> **NCT02793466** · PHASE1 · COMPLETED · sponsor: **Leo Mascarenhas** · enrollment: 15 (actual)

## Conditions studied

- Solid Tumor
- Lymphoma
- Central Nervous System Tumors

## Interventions

- **DRUG:** Durvalumab; MEDI4736

## Key facts

- **NCT ID:** NCT02793466
- **Lead sponsor:** Leo Mascarenhas
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2022-11-30
- **Final completion:** 2023-04-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02793466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02793466, "Durvalumab in Pediatric and Adolescent Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02793466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*